Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitors
This study evaluated disease activity in people with Multiple Sclerosis (PwMS) who received immune checkpoint inhibitors (ICIs) compared to PwMS not treated with ICIs. There were 108 PwMS included (27 PwMS+ICIs and 81 PwMS controls), matched on age, sex, disease duration, DMTs, and MS disease course. Of 27 PwMS+ICIs, one (4%) had a relapse and four (15%) developed new MRI lesions without clinical symptoms. Time to relapse and MRI activity were compared using Kaplan-Meier curves and Cox regression models. There was no significant difference for either time to relapse (p = 0.34) or MRI activity (p = 0.15) in PwMS+ICIs compared to controls.
Authors
- Amy Kunchok (ORCID: https://orcid.org/0000-0002-8387-6491)
- Yadi Li (ORCID: https://orcid.org/0000-0003-4930-2168)
- Marisa McGinley (ORCID: https://orcid.org/0000-0002-7463-6787)
- Wen Wee Ma (ORCID: https://orcid.org/0000-0001-5899-4034)
- Le H. Hua (ORCID: https://orcid.org/0000-0002-0535-3978)
- Lucy Boyce Kennedy (ORCID: https://orcid.org/0000-0001-6644-8922)
- Brittany Lapin (ORCID: https://orcid.org/0000-0002-4314-2282)
- Jeffrey Cohen
- Sidra Afzal (ORCID: https://orcid.org/0000-0002-6312-8146)
Institutions
- Cleveland Clinic (US)
- Lou Ruvo Brain Institute (US)
- Cleveland Clinic Lerner College of Medicine (US)
- Cleveland Clinic Florida (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1002/acn3.52287
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Bristol-Myers Squibb
- Biogen
- Alexion Pharmaceuticals
- Regeneron Pharmaceuticals
- Atara Biotherapeutics
- EpicentRx
- National Institutes of Health
- Agency for Healthcare Research and Quality
- Genentech
- EMD Serono